De-intensification as a new trend in the treatment of type 2
https://doi.org/10.62751/2713-0177-2024-5-2-15
Abstract
Currently, a trend towards deintensification of sugar-lowering therapy has emerged in the domestic and international clinical practice of type 2 diabetes mellitus management. And while recently reducing the intensity of antidiabetic therapy was considered primarily for elderly patients in terms of reducing the risk of hypoglycemia, it is now recognized that many other patients could benefit especially by conversion from intensive insulin therapy regimens to simpler regimens (e. g., fixed combinations of GLP-1 RA and BI). Regimen simplification and reduced number of injections have been shown to improve adherence to therapy without compromising the quality of glycemic control.
About the Authors
E. A. Yanovskaya
Federal State Budgetary Educational Institution of Higher Education Yaroslavl State Medical University of the Ministry of Health of Russia
Elena A. Yanovskaya – Can. Sci. (Med.) Assistant of the Department of Therapy named after Professor E. N. Dormidontov; Endocrinologist of the State Medical Institution of the Yaroslavl region "Regional Clinical Hospital "
Yaroslavl
M. E. Yanovskaya
Federal State Budgetary Educational Institution of Higher Education Yaroslavl State Medical University of the Ministry of Health of Russia
Mariya E. Yanovskaya – Can. Sci. (Med.) Head of the Endocrinology Department
Yaroslavl
E. I. Kaletnik
Endocrinology Research Centre
Elena I. Kaletnik – clinical resident
Moscow
References
1. Kim MJ, Fritschi C. Relationships between cognitive impairment and self-management in older adults with type 2 diabetes: an integrative review. Res Gerontol Nurs. 2021;14(2):104–12
2. Gonzalez JS, Tanenbaum ML, Commissariat PV. Psychosocial factors in medication adherence and diabetes self-management: implications for research and practice. Am Psychol. 2016;71(7):539–551
3. American Diabetes Association Professional Practice Committee; 13. Older Adults: Standards of Care in Diabetes-2024. Diabetes Care 1 January 2024; 47 (Supplement_1): S244–S257. https://doi.org/10.2337/dc24-S013
4. Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016; 10:1299–1307
5. Holman RR, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357(17):1716–1730
6. Munshi MN, et al. Simplification of insulin regimen in older adults and risk of hypoglycemia. JAMA Intern Med. 2016;176(7):1023–1025
7. Taybani Z, et al. Simplifying complex insulin regimens while preserving good glycemic control in type 2 diabetes. Diabetes Ther. 2019;10(5):1869–1878
8. Oktora MP, et al. Rates, determinants and success of implementing deprescribing in people with type 2 diabetes: a scoping review. Diabet Med. 2021;38(2): e14408
9. Seidu S, et al. Deintensification in older patients with type 2 diabetes: a systematic review of approaches, rates and outcomes. Diabetes Obes Metab. 2019;21(7):1668–1679
10. Abdelhafiz AH, Sinclair AJ. Deintensification of hypoglycaemic medications-use of a systematic review approach to highlight safety concerns in older people with type 2 diabetes. J Diabetes Complicat. 2018;32(4):444–450
11. McAlister FA, Youngson E, Eurich DT. Treatment deintensification is uncommon in adults with type 2 diabetes mellitus: a retrospective cohort study. Circ Cardiovasc Qual Outcomes. 2017;10(4): e003514
12. Cristina García-Ulloa A, Jaime-Casas S, Rosado-Lozoya J, et al. De-escalating treatment indications for patients who achieve metabolic goals. Diabetes Res Clin Pract. 2024; 208:111096. doi:10.1016/j.diabres.2024.111096
13. Jude EB, Malecki MT, Gomez Huelgas R, et al. Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in Type 2 Diabetes. Diabetes Ther. 2022;13(4):619–634. doi:10.1007/s13300-022-01222-2
14. Ducat L, Philipson LH, Anderson BJ. The mental health comorbidities of diabetes. JAMA. 2014;312(7):691–692
15. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. – 11-й выпуск – М.; 2023.
16. American Diabetes Association Professional Practice Committee. Summary of revisions: Standards of Care in Diabetes-2024. Diabetes Care 2024;47(Suppl. 1): S5–S10. https://doi.org/10.2337/dc24-SREV
17. Khunti K, Davies MJ. Clinical inertia versus overtreatment in glycaemic management. Lancet Diabetes Endocrinol. 2018;6(4):266–268
18. Ruissen MM, et al. Making diabetes care fit – a re we making progress? Front Clin Diabetes Healthc. 2021 doi: 10.3389/fcdhc.2021.658817
19. Christiaens A, Henrard S, Boland B, Sinclair AJ. Overtreatment of older people with type 2 diabetes-a high impact frequent occurrence in need of a new definition. Diabet Med. 2023;40(2): e14994. doi:10.1111/dme.14994
20. Falcetta P, Nicolì F, Citro F, et al. De-intensification of basal-b olus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes. Acta Diabetol. 2023;60(1):53–60. doi:10.1007/s00592-022-01974-0
21. Bilic-Curcic I, et al. Comparative efficacy and safety of two fixed ratio combinations in type 2 diabetes mellitus patients previously poorly controlled on different insulin regimens: a multi-centric observational study. Eur Rev Med Pharmacol Sci. 2022;26(8):2782–2793. doi:10.26355/eurrev_202204_28608
22. Kalra S, et al. Expert opinion: patient selection for premixed insulin formulations in diabetes care. Diabetes Ther. 2018;9(6):2185–2199
23. Giugliano D, et al. Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2016;51(3):417–428
24. Gomez-Peralta F, et al. Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: a novel, simplified alternative to premix insulin for type 2 diabetes. Diabetes Obes Metab. 2021;23(7):1445–52
25. Mehta R, et al. Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines. Diabetes Obes Metab. 2020;22(11):1961–1975
26. Men P, et al. Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: systematic review, network meta-analysis and cost-effectiveness analysis. Diabetes Obes Metab. 2020;22(1):107–115
27. Rosenstock J, et al. Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial. Diabetes Care. 2021;44(10):2361–70
28. Hart HE, Ditzel K, Rutten GE, et al. De-I ntensification Of Blood Glucose Lowering Medication In People Identified As Being Over-Treated: A Mixed Methods Study. Patient Prefer Adherence. 2019; 13:1775–1783. Published 2019 Oct 18. doi:10.2147/PPA.S208947
Review
For citations:
Yanovskaya E.A., Yanovskaya M.E., Kaletnik E.I. De-intensification as a new trend in the treatment of type 2. FOCUS. Endocrinology. 2024;5(2):31-34. (In Russ.) https://doi.org/10.62751/2713-0177-2024-5-2-15
Views:
188
Email this article 